| Project/Area Number |
23310163
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Chemical biology
|
|---|
| Research Institution | Aichi Medical University (2012-2013)
Keio University (2011) |
|---|
Principal Investigator |
UMEZAWA Kazuo 愛知医科大学, 医学部, 教授 (70114402)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SIMIZU Siro 慶應義塾大学, 理工学部, 准教授 (30312268)
ISHIKAWA Yuichi 慶應義塾大学, 理工学部, 助教 (40348826)
OZAKI Michitaka 北海道大学, 保険科学院, 教授 (80256510)
SAITO Tsuyoshi 慶應義塾大学, 理工学部, 助教 (80609933)
HAGA Sanae 北海道大学, 保険科学院, 研究員 (60706505)
|
|---|
| Project Period (FY) |
2011-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2013: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2012: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2011: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | 分子デザイン / バイオイメージング / 腹腔内転移 / 浸潤 / 遊走 / NF-kappa B / DHMEQ / DTCM-glutarimide / migracin / Exo-ene EQ / pyrapaxilline / 卵巣がん / 転移 / アノイキス / メラノーマ / 卵巣癌 / NF-κB / 探索プローブ / 標的タンパク質 / 光プローブ |
|---|
| Research Abstract |
Purpose of this project is to discover new metastasis inhibitors of low molecular weight from nature and by molecular design. Especially, peritoneal metastasis is very difficult to treat, and wetly to set up bio-imaging system of peritoneal metastasis to evaluate our metastasis inhibitors. Our main discoveries are the followings. 1) We previously discovered NF-kappa B inhibitor DHMEQ. DHMEQ was found to inhibit peritoneal metastasis of highly invasive human gastric cancer cells in mice, in which metastasis was analyzed by bio-imaging. 2) We discovered novel cancer cell migration inhibitor migracin from a microorganism. This inhibitor inhibited migration of human breast carcinoma, fibrosarcoma, and lung carcinoma cells without any cytotoxicity. 3) Glybenclamide is orally active, and widely used for the treatment of type-2 diabetes. In the course of our screening of cancer cell invasion inhibitors, we found that glybenclamide inhibited ovarian cancer cell invasion mediated by PDGF-AA.
|
